

# PRESS RELEASE

Lund - 1 June 2011

**hansa**  
medical

---

---

---

---

## HANSA MEDICAL ARRANGES INFORMATION MEETINGS IN MALMÖ AND STOCKHOLM

**Hansa Medical carries out a new share issue in order to reach crucial and very interesting development milestones, and arranges information meetings in Stockholm and Malmö, Sweden. The company is presented by CEO Emanuel Björne.**

### Information meetings

#### *Stockholm*

Date: Thursday June 9, 2011

Time: 18.00 – 20.00

Venue: Avanza Bank, Regeringsgatan 103, Stockholm

RSVP: At the latest on June 9, Hansa Medical at phone 046-16 56 70 or via e-mail [info@hansamedical.com](mailto:info@hansamedical.com) or notification through the website of Avanza Bank.

#### *Malmö*

Date: Monday June 13, 2011

Time: 18.00 – 20.00

Venue: Comfort Hotel Malmö at Carlsгатan 10 C (by Centralstationen).

RSVP: At the latest on June 9, Hansa Medical at phone 046-16 56 70 or via e-mail [info@hansamedical.com](mailto:info@hansamedical.com) or notification through the website of Avanza Bank.

Please notify your interest as soon as possible since the number of seats is limited.

### Schedule for the new share issue

16 May 2011, Last trading day for the share with right to participate in the share issue

19 May 2011, Record day

23 May 2011, Publication of the prospectus

26 May – 14 June 2011, Subscription period

26 May – 9 June 2011, Subscription rights trading

17 June 2011, Outcome published

The new share issue prospectus and a more general information brochure (in Swedish only) is available at [www.hansamedical.com](http://www.hansamedical.com)

Avanza Bank is the financial advisor and Fredersen Advokatbyrå is the legal advisor of Hansa Medical.

### For further information, please contact:

Hansa Medical AB

Emanuel Björne, CEO

Mobile: +46 707 17 54 77

E-mail: [emanuel.bjorne@hansamedical.com](mailto:emanuel.bjorne@hansamedical.com)

### ABOUT HANSA MEDICAL

Hansa Medical is a biotechnology research and development company focused on the treatment and diagnosis of inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, anti-alpha-11 and HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. Hansa Medical is listed on NASDAQ OMX First North, and Remium AB is the company's Certified Adviser.

Hansa Medical AB  
P.O. Box 785  
SE-220 07 Lund  
Telephone +46 46 16 56 70  
Fax +46 46 12 77 75  
[info@hansamedical.com](mailto:info@hansamedical.com)  
[www.hansamedical.com](http://www.hansamedical.com)

VISITING ADDRESS:  
Scheelevägen 22  
Lund